e-learning
resources
Vienna 2009
Monday, 14.09.2009
New bronchodilators
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Indacaterol once-daily improves health-related quality of life in COPD patients: a 26-week comparison with placebo and tiotropium
A. Yorgancioglu, D. Mahler, A. Iqbal, R. Owen, M. Higgins, B. Kramer (Manisa, Turkey; New Hampshire, East Hanover, United States Of America; Horsham, United Kingdom)
Source:
Annual Congress 2009 - New bronchodilators
Session:
New bronchodilators
Session type:
Thematic Poster Session
Number:
2028
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Yorgancioglu, D. Mahler, A. Iqbal, R. Owen, M. Higgins, B. Kramer (Manisa, Turkey; New Hampshire, East Hanover, United States Of America; Horsham, United Kingdom). Indacaterol once-daily improves health-related quality of life in COPD patients: a 26-week comparison with placebo and tiotropium. Eur Respir J 2009; 34: Suppl. 53, 2028
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Indacaterol once-daily improves health-related quality of life (HRQOL) in COPD patients: a 52-week study
Source: Annual Congress 2009 - New bronchodilators
Year: 2009
A comparative trial of tiotropium, salmeterol and placebo: health-related quality of life
Source: Eur Respir J 2001; 18: Suppl. 33, 26s
Year: 2001
Indacaterol once-daily improves day and night-time symptom control in COPD patients: a 26-week study
versus
placebo and tiotropium
Source: Annual Congress 2009 - New bronchodilators
Year: 2009
NVA237 once daily improves dyspnea and health-related quality of life (HRQoL) in patients with COPD: The GLOW1 trial
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011
Tiotropium + olodaterol fixed-dose combination shows clinically meaningful improvements in quality of life versus placebo
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015
Indacaterol once-daily provides effective 24-h bronchodilation in COPD patients: a 26-week evaluation
vs
placebo and tiotropium
Source: Annual Congress 2009 - New bronchodilators
Year: 2009
Safety and tolerability of indacaterol once-daily in COPD patients versus placebo and tiotropium: a 26-week study
Source: Annual Congress 2009 - New bronchodilators
Year: 2009
Indacaterol once-daily improves dyspnoea in COPD patients: a 26-week placebo-controlled study with open-label tiotropium comparison
Source: Annual Congress 2009 - Next generation bronchodilators
Year: 2009
Health-related quality of life and asthma control in patients treated with budesonide and formoterol in a single inhaler
Source: Eur Respir J 2001; 18: Suppl. 33, 46s
Year: 2001
A placebo controlled trial with inhaled mannitol improves health related quality of life in patients with bronchiectasis
Source: Annual Congress 2004 - Bronchiectasis
Year: 2004
Once-daily QVA149 improves dyspnoea and health status compared with tiotropium plus formoterol in patients without ICS use: A post-hoc analysis of the QUANTIFY study
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
Efficacy and safety of twice-daily aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD
Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators
Year: 2010
Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life
Source: Eur Respir J 2003; 22: Suppl. 45, 51s
Year: 2003
Bronchodilator therapy with indacaterol once-daily in COPD: a 52-week comparison with formoterol
Source: Annual Congress 2009 - Next generation bronchodilators
Year: 2009
Once-daily NVA237 reduces exacerbations and improves symptoms in COPD patients: A pooled analysis of the GLOW1 and GLOW2 studies
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012
QVA149 is more efficacious than tiotropium and salmeterol/fluticasone combination (SFC) in improving patient-reported outcomes and lung function in COPD patients with moderate-to-severe baseline dyspnoea: The IGNITE trials
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015
ACCORD COPD I: Twice-daily aclidinium bromide improves quality of life and dyspnea in COPD patients
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011
Once-daily QVA149 provides the same efficacy as the free combination of its monocomponents indacaterol and glycopyrronium: The BEACON study
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
Salmeterol/fluticasone (seretide, S/F) used as needed improves health-related quality of life in asthmatic adolescents uncontrolled with ICS receiving inhaled short-acting β
2
agonists (SAB2A)
Source: Eur Respir J 2004; 24: Suppl. 48, 380s
Year: 2004
Indacaterol once-daily improves symptom control in COPD patients: a 52-week evaluation
vs
placebo (pbo) and formoterol (for)
Source: Annual Congress 2009 - New bronchodilators
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept